Print

MediciNova, Inc. Receives a Notice of European Patent Allowance for Treating Progressive Multiple Sclerosis  
10/26/2012 6:35:45 AM

SAN DIEGO, Oct. 25, 2012 (GLOBE NEWSWIRE) -- MediciNova Inc, a biopharmaceutical company traded on the NASDAQ Global Market (Nasdaq:MNOV) and the Jasdaq Market of the Osaka Securities Exchange (Code Number: 4875), today announced that it has received a Notice of Allowance from the European Patent Office for a pending patent application which covers the use of ibudilast (MN-166) for the treatment of progressive forms of multiple sclerosis (MS). MN-166 is the company's drug development candidate for certain neurological conditions, including progressive MS, drug addiction and pain.
//-->